Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Finds Fault With Third Duchenne Muscular Dystrophy Drug Filing

Related Content

Catalyst Stumbles With Filing Of Controversial 'Breakthrough Therapy' Firdapse

Feb 17 2016

BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited

Jan 14 2016

Related Companies

PTC Therapeutics, Inc.

BioMarin Pharmaceutical Inc.

Sarepta Therapeutics, Inc.

Catalyst Pharmaceuticals, Inc.

Additional Topics

Regulation BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window